

Merosin-deficient congenital muscular dystrophy in an Omani boy

Amna Al-Futaisi, MD, FRCPC, Almundher Al-Maawali, MD, Raghad Abdwani, MD, Vasudev T. Rao, MD, Hashim Javad, MD, MRCPC, Roshan Koul, DM, FRCPC.

ABSTRACT

الخلل العضلي الولادي الناقص الميروسين، هو من الاضطرابات الصبغية الجسدية المتنحية، والتي قد تظهر في مختلف الأجناس. غالباً ما تظهر على شكل الرضيع المترهل ذو النمو الفكري الطبيعي. يكون كيناز الكرياتينين طبيعياً مع تغييرات في المادة البيضاء في التصوير الدماغي. في هذا التقرير نصف طفل مصاب بالخلل العضلي الولادي الناقص الميروسين، ظهر لديه المرض على شكل تأخر في النمو الحركي و نقص التوتر. ونصف أيضاً، الأعراض السريرية ونتيجة خزعة العضل و الأشعة المغناطيسية للدماغ.

Merosin-deficient congenital muscular dystrophy is an autosomal recessive disease that can manifest differently in different ethnic groups. This often presents as a floppy infant, and normal mental development. The creatine kinase is usually elevated with white matter abnormalities on brain imaging. In this report, we describe an infant with Merosin-deficient congenital muscular dystrophy who presented with delayed motor milestones and hypotonia. The clinical features, biopsy findings, and neuroimaging abnormalities in our patient are described.

Neurosciences 2008; Vol. 13 (3): 305-307

From the Departments of Child Health (Al-Futaisi, Al-Maawali, Abdwani, Javad, Koul) and Pathology (Rao), Sultan Qaboos University Hospital, Muscat, Oman.

Received 16th July 2007. Accepted 17th December 2007.

Address correspondence and reprint request to: Dr. Roshan Koul, Senior Consultant and Child Neurologist, Sultan Qaboos University Hospital, Muscat, Oman. Tel. +968 99210428. E-mail: roshankoul@hotmail.com

Congenital muscular dystrophies (CMDs) are a heterogeneous group of skeletal muscle disorders that typically manifest at birth or within the first few months of life.¹ They are characterized by muscle hypotonia, generalized muscular weakness, and contractures. The

serum creatine kinase level is usually elevated, and muscle biopsies show dystrophic changes.² The muscle histopathology proved merosin-deficient type of CMD in our patient. The rarity of this condition prompted us to report this patient.

Case Report. A first-born male child of cousin related parents was referred to Sultan Qaboos University Hospital, Muscat, Oman at the age of 10 months for evaluation of delayed gross motor milestones. Antenatally, his mother reported reduced fetal movements and had polyhydramnios. He was born at full term by spontaneous vaginal delivery with Apgar scores of 7 and 9 at one and 5 minutes. His cry was instantaneous, but weak and low pitched. He had difficulty breast-feeding due to poor sucking and was nourished by bottle feeds of expressed milk for the first month of life after which he was able to suck adequately. His mother noticed that he was floppy and his limb movements were minimal soon after birth. He also had congenital bilateral talipes equina varus, which was corrected by 3 months of age. His gross motor milestones were noted to be significantly delayed. He was able to support his head with no lag at 8 months of age, turn supine to prone at 10 months, prone to supine at 11 months, and sit without support at 13 months. However, he had been attaining his fine motor skills and social milestones normally. He had pincer grasp, was able to hold a pencil, and had a vocabulary of 15-20 words. He had no respiratory problems. He had no family history of developmental delay, neurological, muscular, or metabolic disorders. His examination at 10 months of age revealed an alert looking infant with growth parameters below the 3rd centile for his age. He had no head lag, but was unable to sit without support. His neurological examination revealed hypotonia with normal muscle bulk, no fasciculations and muscle power of 2/5 to 3/5 of the main groups of muscles. There was hyporeflexia. His cranial nerves and the different sensory modalities were intact. Examinations of the respiratory, cardiovascular, and gastrointestinal systems were unremarkable and he had no joint deformities or




Figure 1 - Cross-section of the normal muscle showing membrane positivity of merosin on laminin $\alpha 2$ stain.




Figure 2 - Cross-section of muscle showing total absence of membrane positivity for merosin on laminin $\alpha 2$ stain.

contractures. Investigations showed a normal routine blood work including a complete blood count, urea and electrolytes, liver function test, and bone profile. The creatine kinase (CK) level was elevated 1979 IU/L (normal 25-195 IU/L). The electromyogram (EMG) revealed myopathic changes and the nerve conduction test was normal. Muscle biopsy of his right quadriceps showed mild variation in the size of fibers, no evidence of regeneration or degeneration, and normal vessels. Immunohistochemistry for muscle membrane proteins dystrophin showed a normal staining pattern (Figure 1). However, laminin $\alpha 2$ staining (Novocastra Laboratories, Newcastle Upon Tyne, United Kingdom, clone number mer 3/22 b2) was negative (Figure 2). Magnetic resonance imaging of the brain with contrast enhancement revealed diffuse, wide spread, white matter changes in both cerebral hemispheres, including the sub cortical white matter, but sparing the basal ganglia and thalami. Lesions appeared hypo intense on T1 and hyper intense on T2. The echocardiogram and chest x-ray were both normal. The parents were counseled, given nutritional advice and regular physiotherapy.

Discussion. The CMDs are autosomal recessive disorders with different clinical phenotypes.² Congenital muscular dystrophy is commonly categorized by the presence or absence of clinically evident cerebral involvement.¹ The classic “pure” form with no CNS involvement is usually found in the western world, while the other form with central nervous involvement, like Fukuyama-type CMD, is found mostly in the Japanese population and muscle-eye and brain syndromes (Walker-Warburg CMD, and Santavouri CMD) found in European regions.³⁻⁶ The pure form of CMD can be further subdivided into merosin positive or merosin-

negative (laminin $\alpha 2$) CMD. The patients with laminin $\alpha 2$ CMD are more severely affected compared with patients of merosin-positive CMD.⁷⁻⁹ Our patient had laminin $\alpha 2$ CMD.

We describe a case of laminin $\alpha 2$ CMD in an Omani patient. There are few reports of CMD from the Middle East mainly Kuwait, Israel, and Jordan.^{2,3,10} The CMD formed 1.6% of cases of all muscle diseases from Jordan.¹⁰ Patients with merosin-negative CMD often present as a floppy infant as our patient. They may show severe neonatal hypotonia, with sucking, swallowing, and respiratory difficulties. Such infants will have generalized motor weakness and decreased spontaneous movements associated with markedly delayed motor development.¹¹ Multiple contractures with joint deformities and kyphoscoliosis are common clinical features, which may develop later during the disease. Cardiac function is usually normal, however, some patients may develop dilated cardiomyopathy.¹² Serum CK is markedly elevated in the early phases of the disease and tends to come down with time, where it could be normal particularly at the age of 5 years or older.¹³ However, normal serum CK level in an infant with suspected CMD makes it very unlikely to be laminin $\alpha 2$ deficient.²

Characteristically, the patients with pure type of CMD have normal mental functions even though in brain imaging white matter changes are constantly being found.¹¹ Philpot et al⁵ postulated that the white matter changes were specific to laminin $\alpha 2$ CMD type patients, than with pure CMD. Merosin is expressed in the fetal brain and this may account for the dysmyelination as seen in the MRI studies.⁷ The EMG is generally considered myogenic as it was found in our patient, but slow motor conduction velocities were found in a series of cases. In

a review of 248 patients with merosin negative CMD, EEG abnormalities were found in a significant number of cases, and clinical seizures were reported in 20% of them.¹³

Muscle biopsy is the gold standard in diagnosing and differentiating congenital muscle diseases.¹ Histologically, laminin $\alpha 2$ congenital CMD shows no specific ultrastructural features, generally they are characterized by large variation in the size of muscle fibers, a few necrotic and regenerating fibers, and marked increase in endomysial collagen tissue, with absent laminin-2 α (merosin) on histochemistry implicated in this disease.¹⁰ Laminins are a family of large extracellular trimeric glycoproteins. Laminin-2 is composed of 3 chains: one heavy ($\alpha 2$) and 2 light chains ($\beta 1$, and $\gamma 1$). Laminin-2 has been shown to be necessary for myogenesis as well as for the survival and stability of myotubes in vitro.¹⁴

Genetically, the human LAMA2 gene was implicated in this disease. There are many mutations described since the first one was identified in 1995.¹⁵ To date no specific treatment is available, but physiotherapy can improve the quality of life by reducing contractures.

References

1. Riggs JE, Bodensteiner JB, Schochet SS Jr. Congenital myopathies/dystrophies. *Neurol Clin* 2003; 21: 779-794. Review.
2. Habeeb YK, Al-Bloushi MA, Al-Jumah ES, De-Souza TM, Moosa A. Congenital muscular dystrophy in Arab children. *J Child Neurol* 2006; 21: 400-405.
3. Rachmiel M, Nevo Y, Lahat E, Kutai M, Harel S, Shahar E. Congenital muscular dystrophy in Israeli families. *J Child Neurol* 2002; 17: 333-336.
4. Dubowitz V, editor. The muscular dystrophies. In: *Muscle Disorders in Childhood*. 2nd ed. London; WB Saunders; 1995. p. 93-105.
5. Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in congenital muscular dystrophy: correlation with expression in merosin in skeletal muscle. *Neuromuscul Disord* 1995; 5: 301-305.
6. Topaloglu H, Evangelism T, Gogus S. Merosin and clinical characteristics of congenital muscular dystrophy in an unselected group of Turkish patients. In: Fukuyama Y, Osawa M, Saito K, editors. *Congenital Muscular Dystrophies*. Tokyo: Elsevier Science BV; 1997. p. 153-168.
7. Hui CM, Kwong L, Lam SY, Loo KT. Merosin-deficient congenital muscular dystrophy in two siblings. *Hong Kong Med J* 2004; 10: 423-426.
8. Kobayashi O, Hayashi Y, Arahata K, Ozawa E, Nonaka I. Congenital muscular dystrophy: Clinical and pathological study of 50 patients with the classical (Occidental) merosin-positive form. *Neurology* 1996; 46: 815-881.
9. Talim B, Kale G, Topaloglu H, Ackoren Z, Caglar M, Gogus S, et al. Clinical and histopathological study of merosin-deficient and merosin-positive congenital muscular dystrophy. *Pediatr Dev Pathol* 2000; 3: 168-176.
10. Abu-Ghalyun Y, Abu-Farsakh H. Preliminary results of muscle disease prevalence in patients from Jordan. *Saudi Med J* 2005; 26: 496-497.
11. Manole E, Alexianu M. Merosin-deficient congenital muscular dystrophy: neuropathology case report. *J Cell Mol Med* 2000; 4: 289-296.
12. Spyrou N, Philpot J, Foale R, Camici PG, Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. *Am Heart J* 1998; 136: 474-476.
13. Dubowitz V. 22nd ENMC sponsored workshop on congenital muscular dystrophy held in Baarn, The Netherlands, 14-16 May 1993. *Neuromuscul Disord* 1994; 4: 75-81.
14. Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. *J Med Genet* 2001; 38: 649-657.
15. Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). *Eur J Hum Genet* 2002; 10: 91-94.

SUPPLEMENTS

- * Supplements will be considered for work including proceedings of conferences or subject matter covering an important topic
- * Material can be in the form of original work or abstracts.
- * Material in supplements will be for the purpose of teaching rather than research.
- * The Guest Editor will ensure that the financial cost of production of the supplement is covered.
- * Supplements will be distributed with the regular issue of the journal but further copies can be ordered upon request.
- * Material will be made available on the Neurosciences website